Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors
Condition(s):Solid Tumor; Colorectal Cancer; Non Small Cell Lung Cancer; Squamous Cell Carcinoma of Head and Neck; Urothelial Carcinoma; Endometrial Cancer; Gastroesophageal Junction Adenocarcinoma; Gastric Adenocarcinoma; Solid Tumors With PIK3Ca MutationLast Updated:October 23, 2023Recruiting